Eugenics Medi Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 04-07-2024
- Paid Up Capital ₹ 2.40 Cr
as on 04-07-2024
- Company Age 18 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 114.56 Cr
as on 04-07-2024
- Satisfied Charges ₹ 72.50 Cr
as on 04-07-2024
- Revenue 34.77%
(FY 2023)
- Profit 50.07%
(FY 2023)
- Ebitda 44.38%
(FY 2023)
- Net Worth 25.87%
(FY 2023)
- Total Assets 59.92%
(FY 2023)
About Eugenics Medi Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.40 Cr.
The company currently has active open charges totaling ₹114.56 Cr. The company has closed loans amounting to ₹72.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ranjeet Singh, Angad Singh, and Gurjeet Kaur serve as directors at the Company.
- CIN/LLPIN
U24232UP2006PTC031683
- Company No.
031683
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Eugenics Medi Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ranjeet Singh  | Managing Director | 24-Apr-2006 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Angad Singh | Director | 01-May-2017 | Current |
| Gurjeet Kaur | Director | 24-Apr-2006 | Current |
Financial Performance of Eugenics Medi Sciences.
Eugenics Medi Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 34.77% increase. The company also saw a substantial improvement in profitability, with a 50.07% increase in profit. The company's net worth Soared by an impressive increase of 25.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eugenics Medi Sciences?
In 2023, Eugenics Medi Sciences had a promoter holding of 93.63% and a public holding of 6.37%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Primewest Marketing Private LimitedActive 12 years 2 months
Ranjeet Singh, Angad Singh and 1 more are mutual person
- Eugenics Medicare Private LimitedActive 16 years 9 months
Ranjeet Singh, Angad Singh and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 25 Sep 2022 | ₹79.50 Cr | Open |
Hdfc Bank Limited Creation Date: 29 Jan 2022 | ₹1.14 Cr | Open |
Tata Capital Financial Services Limited Creation Date: 14 Sep 2021 | ₹4.00 Cr | Open |
How Many Employees Work at Eugenics Medi Sciences?
Eugenics Medi Sciences has a workforce of 802 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eugenics Medi Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eugenics Medi Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
